Lakefront Biotherapeutics NV 6-K, filed Sep 16, 2024
Lakefront Biotherapeutics NV (LKFT)
About this 6-K
Lakefront Biotherapeutics NV filed this 6-K on September 16, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2024
Commission File Number: 001-37384
GALAPAGOS NV
(Translation of registrant's name into English)
Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, and 333-275886).
On September 16, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated September 16, 2024
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GALAPAGOS NV | ||
| (Registrant) | ||
| Date: September 16, 2024 | /s/ Annelies Denecker | |
| Annelies Denecker | ||
| Company Secretary | ||
EXHIBIT 99.1
Galapagos receives transparency notification from EcoR1 Capital
Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ:
GLPG) received a transparency notification from EcoR1 Capital LLC.
Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 13 September 2024 on behalf of Mr. Oleg Nodelman and EcoR1 Capital LLC, who notified that EcoR1 Capital LLC holds 6,713,553 of Galapagos’ voting rights, consisting of 839,388 ordinary shares and 5,874,165 American Depository Receipts, further to an acquisition of voting securities and financial instruments that are treated as voting securities.
EcoR1 Capital LLC, controlled by Mr. Oleg Nodelman, controls investment funds EcoR1 Capital Fund Qualified LP and EcoR1 Capital Fund LP, which all together hold 6,713,553 of Galapagos’ voting rights. This represents 10.19% of Galapagos’ currently outstanding 65,897,071 shares. EcoR1 Capital LLC thus crossed above the 10% threshold of Galapagos’ voting rights by acquisition of voting securities on 10 September 2024. The transparency notification furthermore specifies that (i) the 6,713,553 voting rights are beneficially owned by clients of EcoR1 Capital Fund Qualified LP and EcoR1 Capital Fund LP and that these clients include, among others, individuals, endowments, foundations and pooled investment vehicles, and (ii) EcoR1 Capital LLC is the discretionary investment advisory manager and exercises the voting rights of its entities at its discretion in the absence of specific instructions. The full transparency notification is available on the Galapagos website.
About Galapagos
We are a biotechnology company with operations in Europe and the U.S. dedicated
to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize
compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies
in oncology and immunology. With capabilities from lab to patient, including a decentralized cell therapy manufacturing network, we are
committed to challenging the status quo and delivering results for our patients, employees, and shareholders. For additional information,
please visit www.glpg.com or follow us on LinkedIn or X.
For further information, please contact:
| Media inquiries: Marieke Vermeersch +32 479 490 603 media@glpg.com Jennifer Wilson +44 7444 896759 media@glpg.com |
Investor inquiries: Sofie Van Gijsel +1 781 296 1143 ir@glpg.com Sandra Cauwenberghs +32 495 584 663 ir@glpg.com |
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.